Fig. 4: Immunogenicity of mRNA-native BA.4/5 and mRNA-VLP vaccines in naive mice. | npj Vaccines

Fig. 4: Immunogenicity of mRNA-native BA.4/5 and mRNA-VLP vaccines in naive mice.

From: Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2

Fig. 4

Groups of naive BALB/c mice (n = 6/group) were administered 1.0 μg of LNP-formulated mRNA vaccine (mRNA-native BA.4/5, mRNA-VLP D614G, or mRNA-VLP BA.4/5) or PBS control intramuscularly on study days 1 and 21. Fourteen days following the second dose (study day 35), sera were collected and pseudovirus-based neutralization assays performed using a panel of SARS-CoV-2 pseudoviruses (pV) as indicated. The geometric mean titer (GMT) ± geometric standard deviation is shown with indicated p value comparing the different vaccine group responses for each tested pV by Kruskal–Wallis test, the dotted horizontal line indicates the assay lower limit of detection (LLD). Ab antibody, D614G ancestral D614G spike, ID50 half-maximal inhibitory dilution, native full-length spike protein containing the S2P pre-fusion spike stabilization mutations, ns not significant, PBS phosphate-buffered saline, pV pseudovirus, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, VLP virus-like particle; *p < 0.05; **p < 0.01; ***p < 0.001.

Back to article page